{"id":"pramlintide-and-glucagon","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2103758","moleculeType":"Protein","molecularWeight":"3949.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pramlintide is an amylin analog that modulates postprandial glucose excursions by delaying gastric emptying, suppressing glucagon secretion, and promoting satiety. Glucagon, a counter-regulatory hormone, rapidly raises blood glucose levels to prevent or treat hypoglycemic episodes. Together, this combination aims to improve glycemic control while reducing hypoglycemia risk in diabetes management.","oneSentence":"This combination uses pramlintide to slow gastric emptying and suppress glucagon secretion, while glucagon provides a rapid-acting counter-regulatory hormone to prevent hypoglycemia.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:29:47.548Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03547427","phase":"NA","title":"Glucagon Counterregulation in Type 1 Diabetes","status":"TERMINATED","sponsor":"University of Virginia","startDate":"2018-05-20","conditions":"Type 1 Diabetes Mellitus","enrollment":13},{"nctId":"NCT00950677","phase":"PHASE4","title":"The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2009-07","conditions":"Type 2 Diabetes","enrollment":16},{"nctId":"NCT00206258","phase":"PHASE3","title":"The Role of Amylin and Glucagon in T1DM","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2002-07","conditions":"Type 1 Diabetes","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pramlintide and glucagon","genericName":"Pramlintide and glucagon","companyName":"Baylor College of Medicine","companyId":"baylor-college-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pramlintide is used in combination with basal insulin to treat Type 1 and Type 2 Diabetes, as well as Type 1 Diabetes Mellitus, according to ClinicalTrials.gov. Glucagon is studied in relation to counterregulation in Type 1 Diabetes, as seen in the ClinicalTrials.gov study \"Enhancement of Glucagon Counterregulation in Type 1 Diabetes by Basal Amylin Replacement\".","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}